We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-6.61%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$670M
AUM Growth
+$109M
Cap. Flow
+$144M
Cap. Flow %
21.49%
Top 10 Hldgs %
59.4%
Holding
184
New
14
Increased
76
Reduced
55
Closed
39

Top Buys

Rank Stock Value
1
ETP
Energy Transfer Partners, L.P.
ETP
+$71.8M
2
WPZ
Williams Partners L.P.
WPZ
+$17.8M
3
BPL
Buckeye Partners, L.P.
BPL
+$15M
4
EPD icon
Enterprise Products Partners
EPD
+$13.8M
5
ET icon
Energy Transfer Partners
ET
+$13.6M

Top Sells

Rank Stock Value
1
ETP
Energy Transfer Partners L.p.
ETP
+$45.5M
2
SHV icon
iShares 0-1 Year Treasury Bond ETF
SHV
+$34.1M
3
MPC icon
Marathon Petroleum
MPC
+$6.13M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$4.81M
5
SSO icon
ProShares Ultra S&P500
SSO
+$4.67M

Sector Composition

Rank Sector Weight
1 Energy 73.91%
2 Healthcare 7.71%
3 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SHLX
76
DELISTED
Shell Midstream Partners, L.P.
SHLX
$445K 0.07%
14,676
+328
+2% +$10.2K
BPMC
77
DELISTED
Blueprint Medicines
BPMC
$391K 0.06%
7,718
-2,972
-28% -$126K
ESPR
78
DELISTED
Esperion Therapeutics
ESPR
$389K 0.06%
8,404
-14,369
-63% -$528K
JUNO
79
DELISTED
Juno Therapeutics, Inc.
JUNO
$387K 0.06%
12,957
-2,697
-17% -$66.6K
RETA
80
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$372K 0.06%
11,743
-1,166
-9% -$28.7K
DVAX
81
DELISTED
Dynavax Technologies
DVAX
$368K 0.05%
+38,177
New +$248K
EPZM
82
DELISTED
Epizyme, Inc
EPZM
$366K 0.05%
24,266
-1,062
-4% -$16.1K
IOVA icon
83
Iovance Biotherapeutics
IOVA
$2.29B
$364K 0.05%
49,536
+10,116
+26% +$64.3K
RXDX
84
DELISTED
Ignyta, Inc.
RXDX
$361K 0.05%
+34,848
New +$283K
SGMO
85
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$352K 0.05%
+39,959
New +$256K
FOLD
86
DELISTED
Amicus Therapeutics
FOLD
$350K 0.05%
34,727
-13,116
-27% -$106K
AVXS
87
DELISTED
AveXis, Inc. Common Stock
AVXS
$346K 0.05%
4,212
-1,373
-25% -$103K
KITE
88
DELISTED
Kite Pharma, Inc.
KITE
$346K 0.05%
3,340
-2,537
-43% -$207K
ITCI
89
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$345K 0.05%
27,801
+9,472
+52% +$110K
IMMU
90
DELISTED
Immunomedics Inc
IMMU
$343K 0.05%
38,871
-36,163
-48% -$254K
ONC
91
BeOne Medicines Ltd
ONC
$33.9B
$340K 0.05%
7,553
-2,116
-22% -$83.4K
CTMX icon
92
CytomX Therapeutics
CTMX
$725M
$339K 0.05%
+21,875
New +$330K
AGEN
93
Agenus
AGEN
$258M
$336K 0.05%
4,375
+996
+29% +$70K
AIMT
94
DELISTED
Aimmune Therapeutics
AIMT
$334K 0.05%
16,261
+3,789
+30% +$72.3K
TCRT icon
95
Alaunos Therapeutics
TCRT
$4.69M
$333K 0.05%
357
+59
+20% +$57.8K
ONCE
96
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$332K 0.05%
5,552
+191
+4% +$10.7K
KYNB
97
Kyntra Bio
KYNB
$28.6M
$331K 0.05%
410
-140
-25% -$97.5K
MCRB icon
98
Seres Therapeutics
MCRB
$50.6M
$331K 0.05%
1,466
-91
-6% -$18.7K
PBYI icon
99
Puma Biotechnology
PBYI
$408M
$329K 0.05%
3,767
-4,380
-54% -$245K
PTCT icon
100
PTC Therapeutics
PTCT
$6.51B
$327K 0.05%
17,818
-4,881
-22% -$65.8K
2 3
4
5 6

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
OC
Optima Capital Beaverton, Oregon $215M AUM 17.28% 1-Year Est. Return
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return

Virtus ETF Advisers's Q2 2017 Portfolio in Review

As of Q2 2017, Virtus ETF Advisers held 184 positions worth $670M, up 19% from $562M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Virtus ETF Advisers deployed $144M of net new capital in Q2 2017, opening 14 new positions and adding to 76 existing holdings. Its largest new stake was Jounce Therapeutics, Inc. Common Stock: 18,442 shares worth $259K.

By sector, the portfolio is most concentrated in Energy at 74% of assets, up from 70% a quarter earlier, followed by Healthcare and Utilities.

On the sell side, the largest reduction was Marathon Petroleum, an estimated $6.13M trimmed.

  • Virtus ETF Advisers's largest Q2 2017 buy was Jounce Therapeutics, Inc. Common Stock: 18,442 shares worth $259K.
  • Virtus ETF Advisers added most to Energy Transfer Partners, L.P. in Q2 2017, an estimated $71.8M increase.
  • Virtus ETF Advisers's biggest Q2 2017 reduction was Marathon Petroleum, cutting an estimated $6.13M.
  • Virtus ETF Advisers fully exited Energy Transfer Partners L.p. in Q2 2017, selling an estimated $45.5M.
  • Virtus ETF Advisers's ten largest holdings make up 59% of its $670M portfolio in Q2 2017.
  • Virtus ETF Advisers opened 14 new positions and closed 39 in Q2 2017.
  • Virtus ETF Advisers's portfolio value rose 19% quarter-over-quarter to $670M.

Based on Virtus ETF Advisers's 13F filing for Q2 2017, filed 14 Aug 2017.